Traders should monitor upcoming IND submission for AKTX-101 as a near-term catalyst; the WuXi XDC partnership reduces technical risk and may attract future licensing interest, especially given PH1's novel mechanism in a high-demand ADC market.
Price Chart
Executive Summary
Akari Therapeutics announced a strategic partnership with WuXi XDC to accelerate development of its antibody drug conjugate (ADC) programs, particularly AKTX-101, with an anticipated IND filing by late 2026. The collaboration enhances platform validation and reduces execution risk, positioning Akari within the growing ADC landscape.
Key Facts
- Strategic partnership with WuXi XDC, a global leader in ADC development and manufacturing
- Partnership extends beyond traditional CDMO engagement, supporting accelerated development
- AKTX-101 IND filing expected in late 2026, with first-in-human trials by late 2026/early 2027
- PH1 payload platform validated through collaboration, enabling efficient advancement of ADC candidates
Financial Impact
Non-dilutive strategic collaboration enhancing development efficiency and de-risking clinical advancement
Risk Factors
- Dependence on successful IND acceptance and clinical trial initiation
- Need for additional capital to fund development beyond current milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270992 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | DEF 14A | $8.72 | awaiting T+60 | — | $8.58 (−1.61%) |
Oct 1, 2026 26d ago | 8-K | $8.72 | awaiting T+60 | — | $8.58 (−1.61%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $8.58 (+13.79%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $8.58 (+36.07%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $8.58 (−39.62%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $8.58 (+17.58%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.58 (−11.46%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.58 (−11.46%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $8.58 (−61.09%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $8.58 (+51.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers